Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Colorcon
Express Scripts
Fuji
Cantor Fitzgerald
Accenture
Novartis
Fish and Richardson
Medtronic
Dow

Generated: August 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:Compounds of the formula ##STR1## of which, in exemplary compounds, the thienyl group is attached via the 2-position and: (a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl; (b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl; (c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and, (d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl. These are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s): Banholzer; Rolf (Ingelheim am Rheim, DE), Bauer; Rudolf (Wiesbaden, DE), Reichl; Richard (Ingelheim am Rheim, DE)
Assignee: Boehringer Ingelheim GmbH (Ingelheim am Rhein, DE)
Application Number:08/405,111
Patent Claims: 1. A compound of the formula ##STR26## wherein Q is a group of the formula --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or ##STR27## R and R' are each independently C.sub.1 -C.sub.4 -alkyl; R.sub.1 is thienyl, phenyl, cyclopentyl or cyclohexyl; and,

X.sup.- is a physiologically acceptable anion.

2. A compound in accordance with claim 1, of the formula ##STR28## wherein R is CH.sub.3, C.sub.2 H.sub.5, n-C.sub.3 H.sub.7, or i-C.sub.3 H.sub.7 ;

R' is CH.sub.3 ; and,

R.sub.1, Q and X.sup.- are as defined in claim 1.

3. A compound in accordance with claim 2 wherein R.sub.1 is thienyl.

4. A compound in accordance with claim 2 wherein X.sup.- is Br.sup.- or CH.sub.3 SO.sub.3.

5. A compound of the formula ##STR29## wherein X.sup.- is a physiologically acceptable anion.

6. A compound of the formula ##STR30## wherein X.sup.- is a physiologically acceptable onion.

7. A compound of the formula ##STR31##

8. A compound of the formula ##STR32## wherein R.sub.1 is 2-thienyl and A is 3.alpha.-(6,7-dehydro)-tropanyl methobronide.

9. A compound of the formula ##STR33## wherein R.sub.1 is 2-thienyl and A is 3.beta.-tropanyl methobromide.

10. A compound of the formula ##STR34## wherein R.sub.1 is cyclopentyl and A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide.

11. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4 6, 7, 8, 9, 10.

12. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

13. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

14. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

15. A pharmaceutical composition, for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

16. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Fuji
Dow
Daiichi Sankyo
Boehringer Ingelheim
Colorcon
Julphar
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot